pharma · Unresectable Hepatocellular Carcinoma (HCC) · Unexplained Recurrent Miscarriage and Recurrent Implantation Failure
Zenshine Pharmaceuticals
Nanjing Zenshine Pharmaceuticals
Zenshine Pharmaceuticals clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2018
- Employees
- 12
- Programs
- 8
- Drugs
- 17
- Patents
- 0
Zenshine Pharmaceuticals projects
4 ClinicalTrials.gov programs sponsored by Zenshine Pharmaceuticals.
Zenshine Pharmaceuticals has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Camrelizumab Plus Apatinib
Nanjing Zenshine Pharmaceuticals
Unresectable Hepatocellular Carcinoma (HCC)
1 trial -
Pre-operative chemotherapy
Nanjing Zenshine Pharmaceuticals
Gastric Cancers
1 trial -
Rezvilutamide
Nanjing Zenshine Pharmaceuticals
Prostate Cancer
1 trial -
low-dose lymphocyte immunotherapy
Nanjing Zenshine Pharmaceuticals
Unexplained Recurrent Miscarriage and Recurrent Implantation Failure
1 trial
Frequently asked questions
How many clinical projects does Zenshine Pharmaceuticals have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.